IL-32 Levels in Patients With Chronic Periodontitis
Primary Purpose
Periodontitis
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
nonsurgical periodontal treatment
Gingival crevicular fluid and saliva collection
Sponsored by
About this trial
This is an interventional diagnostic trial for Periodontitis focused on measuring Interleukin-32, periodontitis
Eligibility Criteria
Inclusion Criteria:
- all subjects in the study were possess of at least 20 teeth excluding third molars.
Exclusion Criteria:
- agressive periodontitis,
- periapical pathologies,
- excessive forces including mechanical forces caused by orthodontic forces and occlusal forces;
- presence of systemic diseases;
- administration of non-steroidal and anti-inflammatory drugs or antibiotic therapies within the previous 6 months;
- need for antibiotic prophylaxis for dental treatment and having received non-surgical periodontal treatment within the past 6 months or surgical periodontal treatment within the past 12 months;
- allergy or sensitivity to any drug,
- pregnancy,
- lactation, and
- current and former use of tobacco.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
chronic periodontitis patients
periodontally healthy controls
Arm Description
gingival crevicular fluid and saliva collecion were taken before and after nonsurgical periodontal treatment
gingival crevicular fluid and saliva collection were taken at baseline after oral hygiene instructions
Outcomes
Primary Outcome Measures
Biochemical parameters (IL-32, IL-10 and THF-alpha)
The changes in levels of IL-32 after periodontal treatment determined by ELISA. The changes in levels of IL-32 were analyzed to determine diagnostic and prognostic potential as a biomarker of periodontitis.
Secondary Outcome Measures
Probing pocket depth
The changes in probing pocket depth after periodontal treatment.Probing pocket depth was measured for determining severity of disease and clinic outcome.
Probing pocket depth and clinical attachment level
The changes in clinical attachment level after periodontal treatment. The probing depth and the distance from the gingival margin to the cemento-enamel junction are used to measurement of clinical attachment level. Clinical attachment level was measured for determining severity of disease and clinic outcome.
Gingival index
The changes in gingival index after periodontal treatment. Gingival index was recorded for classifying and evaluating (coronally) gingival inflammation.
Plaque index
The changes in plaque index after periodontal treatment. Plaque index was recorded for determining and classifying oral hygiene status.
Bleeding on probing
The changes in bleeding on probing after periodontal treatment. Bleeding on probing was recorded for classifying and evaluating (apically) gingival inflammation.
Full Information
NCT ID
NCT02632981
First Posted
December 10, 2015
Last Updated
December 16, 2015
Sponsor
Bulent Ecevit University
1. Study Identification
Unique Protocol Identification Number
NCT02632981
Brief Title
IL-32 Levels in Patients With Chronic Periodontitis
Official Title
IL-32 Levels in Gingival Crevicular Fluid and Saliva of Patients With Chronic Periodontitis After Periodontal Treatment.
Study Type
Interventional
2. Study Status
Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
July 2014 (undefined)
Primary Completion Date
May 2015 (Actual)
Study Completion Date
July 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Bulent Ecevit University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Interleukin-32 (IL-32) is a recently described cytokine that is a strong inducer of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α. A previous report have reported that Porphyromonas gingivalis-derived LPS significantly up-regulated IL-32 expression compared with the unstimulated cells in monocytes (THP-1 cells). They suggested that IL-32 may contribute to the pathogenesis of periodontal disease. In the present study the investigators hypothesized that IL-32 levels may increase in the gingival crevicular fluid (GCF) and saliva of patients with chronic periodontitis compared with healthy controls and these levels may decrease together with treatment.
Detailed Description
The purpose of this study was to investigate IL-32 levels in the GCF and saliva of patients with chronic periodontitis and to evaluate changes after nonsurgical periodontal therapy.
Twenty-seven CP and 27 periodontally healthy controls were enrolled in this study. Periodontitis patients received nonsurgical periodontal treatment. GCF and saliva sampling and clinical periodontal parameters were assessed before and a month after treatment. IL-32, IL-10 and TNF-α levels in GCF and saliva were measured by enzyme-linked immunosorbent assay.
Unstimulated salivary samples were collected using standard techniques. About 2 mL whole saliva was collected in disposable tubes and centrifuged immediately to remove cell debris (10,000 g x 10 minutes). The supernatants (50µL each) were stored at -40C until analyzed. GCF samples were collected from a mesio-buccal and disto-palatal site on each tooth. In the CP group, the samples were obtained from patients at areas with ≥5 mm CAL, ≥6 mm PD and ≥30% bone loss. In the healthy group, GCF samples were collected from teeth exhibiting PD<3 mm without CAL and BOP. The area was isolated with cotton rolls, saliva contamination elimination was ensured, and it was slightly air dried. GCF was sampled with paper strips. Paper strips were placed into the crevice until mild resistance was felt (intracrevicular method) and left in the position for 30 seconds. Strips contaminated with blood or saliva were discarded. Each sampled strip was placed into a 400µl eppendorf centrifuge tube and stored at -40C until analyzed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Periodontitis
Keywords
Interleukin-32, periodontitis
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
54 (Actual)
8. Arms, Groups, and Interventions
Arm Title
chronic periodontitis patients
Arm Type
Active Comparator
Arm Description
gingival crevicular fluid and saliva collecion were taken before and after nonsurgical periodontal treatment
Arm Title
periodontally healthy controls
Arm Type
Placebo Comparator
Arm Description
gingival crevicular fluid and saliva collection were taken at baseline after oral hygiene instructions
Intervention Type
Other
Intervention Name(s)
nonsurgical periodontal treatment
Other Intervention Name(s)
chronic periodontitis patients
Intervention Description
Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
Intervention Type
Other
Intervention Name(s)
Gingival crevicular fluid and saliva collection
Other Intervention Name(s)
periodontally healthy controls, chronic periodontitis patients
Intervention Description
GCF collection with filter paper (Periopaper) using the intracrevicular method. Patients' mouths were rinsed with distilled water, and unstimulated salivary samples were collected by patients expectorating into disposable tubes.
Primary Outcome Measure Information:
Title
Biochemical parameters (IL-32, IL-10 and THF-alpha)
Description
The changes in levels of IL-32 after periodontal treatment determined by ELISA. The changes in levels of IL-32 were analyzed to determine diagnostic and prognostic potential as a biomarker of periodontitis.
Time Frame
Baseline and 1 month after treatment
Secondary Outcome Measure Information:
Title
Probing pocket depth
Description
The changes in probing pocket depth after periodontal treatment.Probing pocket depth was measured for determining severity of disease and clinic outcome.
Time Frame
Baseline and 1 month after treatment
Title
Probing pocket depth and clinical attachment level
Description
The changes in clinical attachment level after periodontal treatment. The probing depth and the distance from the gingival margin to the cemento-enamel junction are used to measurement of clinical attachment level. Clinical attachment level was measured for determining severity of disease and clinic outcome.
Time Frame
Baseline and 1 month after treatment
Title
Gingival index
Description
The changes in gingival index after periodontal treatment. Gingival index was recorded for classifying and evaluating (coronally) gingival inflammation.
Time Frame
Baseline and 1 month after treatment
Title
Plaque index
Description
The changes in plaque index after periodontal treatment. Plaque index was recorded for determining and classifying oral hygiene status.
Time Frame
Baseline and 1 month after treatment
Title
Bleeding on probing
Description
The changes in bleeding on probing after periodontal treatment. Bleeding on probing was recorded for classifying and evaluating (apically) gingival inflammation.
Time Frame
Baseline and 1 month after treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
all subjects in the study were possess of at least 20 teeth excluding third molars.
Exclusion Criteria:
agressive periodontitis,
periapical pathologies,
excessive forces including mechanical forces caused by orthodontic forces and occlusal forces;
presence of systemic diseases;
administration of non-steroidal and anti-inflammatory drugs or antibiotic therapies within the previous 6 months;
need for antibiotic prophylaxis for dental treatment and having received non-surgical periodontal treatment within the past 6 months or surgical periodontal treatment within the past 12 months;
allergy or sensitivity to any drug,
pregnancy,
lactation, and
current and former use of tobacco.
12. IPD Sharing Statement
Learn more about this trial
IL-32 Levels in Patients With Chronic Periodontitis
We'll reach out to this number within 24 hrs